Indication

Target/marker/pathway

Summary

Licensing status

Publication and contact information

Various

Hypertension; renal disease

Uromodulin (UMOD; THP); solute carrier family 12 potassium-chloride transporter member 1 (SLC12A1; NKCC2)

In vitro and mouse studies suggest inhibiting UMOD could help treat hypertension and chronic kidney disease. In nephrectomy samples from patients homozygous for a UMOD promoter region risk allele that is associated with hypertension and chronic kidney disease risk, UMOD expression was twofold higher than that in samples from patients homozygous for a protective allele. In mice, transgenic overexpression of Umod caused salt-sensitive hypertension and renal damage and increased activity of the Nkcc2 sodium transporter compared with wild-type Umod expression. In the mice, an NKCC2 inhibitor decreased blood pressure compared with no treatment. Next steps could include developing UMOD inhibitors.

SciBX 6(48); doi:10.1038/scibx.2013.1401
Published online Dec. 19, 2013

Patent and licensing status unavailable

Trudu, M. et al. Nat. Med.;
published online Nov. 3, 2013;
doi:10.1038/nm.3384
Contact: Luca Rampoldi, San Raffaele Scientific Institute, Milan, Italy
e-mail:
rampoldi.luca@hsr.it
Contact: Olivier Devuyst, University of Zurich, Zurich, Switzerland
e-mail:
olivier.devuyst@uzh.ch